Latest Breaking News On - Daewoong pharmaceutical co - Page 1 : comparemela.com

AEON Biopharma Reports First Quarter 2024 Financial Results

Aeon's Migraine: Stock Plummets as Drug Test Fails - Orange County Business Journal

Aeon Biopharma Inc.’s stock plunged 53% in intraday trading May 3 on the company’s announcement of disappointing results from testing of its migraine drug. The Irvine-based clinical-stage company (NYSE: AEON) said its ABP-450 treatment for the prevention of chronic migraine did no better than placebo in a Phase 2 trial.

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

AEON Biopharma Reports Fourth Quarter and Full Year 2023

– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive.

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results